I-Mab is a biopharmaceutical company that is dedicated to discovering and developing innovative biologics to address unmet medical needs. Their corporate philosophy revolves around a patient-centric approach, focusing on improving patients' lives through advanced therapies. I-Mab values integrity, collaboration, and scientific excellence, aiming to provide breakthrough treatments for diseases with high unmet medical needs. With a strong commitment to delivering novel solutions, I-Mab continuously strives to be at the forefront of research and development in the biopharmaceutical industry.

I-Mab is primarily present in China and the United States.

I-Mab, a leading biopharmaceutical company, has achieved significant milestones throughout its journey. The company successfully conducted a Phase 3 clinical trial for its innovative therapy in treating diffuse large B-cell lymphoma, demonstrating its commitment to advancing healthcare solutions. Additionally, I-Mab received the U.S. FDA Fast Track Designation for its potential treatment of multiple myeloma, recognizing the company's dedication to developing breakthrough therapies. Furthermore, I-Mab forged strategic partnerships with renowned global pharmaceutical companies, reinforcing its position in the global market. Overall, I-Mab's achievements highlight its exceptional growth and commitment towards improving patients' lives through groundbreaking treatments.

I-Mab is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer and autoimmune diseases. Founded in 2016, I-Mab focuses on the discovery and development of antibody-based drugs by leveraging its proprietary discovery and development platforms. This Chinese company has a strong emphasis on research and development, working on a diverse pipeline of potential drugs targeting various diseases. With a commitment to delivering novel and effective solutions, I-Mab has garnered recognition within the pharmaceutical industry for its innovative approach and dedication to improving patients' lives.

The main competitors of I-Mab in the market include large biopharmaceutical companies such as Junshi Biosciences, Legend Biotech, BeiGene, and Innovent Biologics.

I-Mab is primarily active in the pharmaceutical industry.

I-Mab is a clinical-stage biopharmaceutical company based in China. Its business model revolves around the discovery, development, and commercialization of innovative and differentiated biologics. I-Mab focuses on developing novel antibodies to address unmet medical needs in the fields of oncology, immuno-oncology, and autoimmune diseases. With a strong pipeline of potential therapies, I-Mab aims to bring groundbreaking treatments to patients globally. By advancing its drug candidates through rigorous research and strategic partnerships, I-Mab aims to revolutionize healthcare and improve patient outcomes.

P/E odnos I-Mab iznosi -3,85.

KUV kompanije I-Mab iznosi 2.306,03.

AlleAktien kvalitativni skor za I-Mab je 1/10.

očekivana I-Mab promet je 765.000,00 CNY.

Dobit očekivana I-Mab je -458,28 mil. CNY.

I-Mab is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for serious diseases like cancer and immune disorders. They have a strong pipeline of products in the fields of oncology, autoimmune diseases, and cardiovascular diseases. They have partnerships with other companies to market their products worldwide. Overall, their business model is centered around developing and marketing effective therapies for challenging diseases and they have a unique partnership strategy.

I-Mab isplaćuje dividendu od 0 CNY raspoređenu preko isplata u toku godine.

Dividenda za I-Mab trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od I-Mab je US44975P1030.

WKN od I-Mab je A2PVC6.

Oznaka za praćenje akcija kompanije I-Mab je IMAB.

U poslednjih 12 meseci, I-Mab je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, I-Mab će verovatno isplatiti dividendu od 0 CNY.

Dividendski prinos od I-Mab trenutno iznosi .

I-Mab isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

I-Mab je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 CNY. To odgovara dividendnom prinosu od 0 %.

I-Mab se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od I-Mab od 26. 8. 2024. u iznosu od 0 CNY, morali ste da imate akciju u depou pre Ex-dana 26. 8. 2024..

Isplata poslednje dividende izvršena je 26. 8. 2024..

U godini 2023 kompanija I-Mab je isplatila 0 CNY kao dividende.

Dividende od I-Mab se isplaćuju u CNY.